Trial Profile
A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients With Metastatic or Recurrent Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jul 2019
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Nippon Kayaku
- 12 Feb 2019 Primary endpoint (Progression free survival) has not been met, as per results has not been met.
- 12 Feb 2019 Results published in the British Journal of Cancer
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress